Phone (336) 292-1510
Fax (336) 292-0679

Receive our eNewsletter

  Home  
  Our Team  
  Patient Info  
  Services  

News for Healthier Living

EGFR Inhibitor-Linked Cytokine Storms: Study Uncovers the Trigger

In a recent study, researchers have uncovered the biological trigger behind the dangerous immune-related adverse events (irAEs) that occur when the epidermal growth factor receptor (EGFR) inhibitor osimertinib is combined with immune checkpoint inhibitors (ICIs). Using a preclinical mouse model, the team found that this drug duo activates the IL-6/JAK/STAT3 signaling pathway in liver macrophages, unleashing a cytokine storm-like inflammatory response. Importantly, the addition of the JAK inhibitor ruxolitinib successfully dampened this response, significantly lowering levels of key inflammatory markers in the bloodstream. These findings point to a viable path forward in reducing the life-threatening toxicity associated with combination cancer therapies.

June 5, 2025


June 6 2025

June 5 2025

June 4 2025

June 3 2025

June 2 2025

June 1 2025

May 31 2025

May 30 2025

May 29 2025

May 28 2025

May 27 2025

May 26 2025

May 25 2025

May 24 2025

May 23 2025